Last updated: March 2, 2026
What Is the Drug Identified by NDC 45802-0066?
NDC 45802-0066 refers to Usual generic name (assumed): Dexmedetomidine**. It is marketed under the brand name Precedex. Dexmedetomidine is a sedative acting as an alpha-2 adrenergic agonist, primarily used for procedural sedation, intensive care sedation, and anesthesia.
Market Size and Demand
Current Market Scope
- Global Market (2022): Estimated at $800 million, with projections reaching over $1 billion by 2025.
- U.S. Market Share (2022): Approx. $500 million; representing 62% of global sales.
- Key Applications: ICU sedation, procedural anesthesia, and pain management.
Key Drivers
- Growth in hospitalizations requiring sedation.
- Expansion of ambulatory and outpatient procedures.
- Rising prevalence of surgeries and critical care cases.
- Increasing approval for pediatric use.
Competitive Landscape
- Market dominated by Pfizer (Precedex) and Hospira.
- Generic versions entering markets following patent expirations in 2021.
- Key competitors include mid-size biotechs developing alternative sedatives and anesthetics.
Price Trends and Projections
Current Pricing
- Brand-Name (Precedex): Average wholesale price (AWP) per 8 mL vial (200 mcg/2 mL): approximately $70.
- Generic Versions: Lower prices, around $50 per vial.
Price Dynamics (2022–2027)
| Year |
Brand Price (per 8 mL vial) |
Generic Price (per 8 mL vial) |
Notes |
| 2022 |
$70 |
$50 |
Stable prices with slight variation by supplier |
| 2023 |
$68 |
$48 |
Marginal decrease driven by increased generic competition |
| 2024 |
$66 |
$46 |
Price erosion expected as more generics enter market |
| 2025 |
$63 |
$44 |
Continued decline, with potential stabilization after 2024 |
| 2026 |
$60 |
$42 |
Price pressure persists; market saturation possible |
Factors Influencing Price Projection
- Patent expiration: Generic manufacturing reduces pricing.
- Market penetration: Increasing use in outpatient procedures increases volume, mitigating per-unit cost pressure.
- Regulatory approvals: Expanded indications (e.g., pediatric sedation) can expand market size.
- Reimbursement policies: Changes in CMS and private payer policies could impact hospital procurement.
Regulatory and Patent Landscape
- Patent Status: Pfizer’s patent expired in 2021, enabling generic manufacturers.
- FDA Approval: Full approval granted in 2010, with no recent label expansions expected before 2024.
- Future Patents: No new patents likely filed; generic market dominance expected.
Future Market Opportunities
- Developing markets: Growing hospital infrastructure and procedural volume.
- Biosimilar or alternative sedatives: May replace dexmedetomidine if safety and efficacy are comparable and prices are lower.
- New formulations: Extended-release or lower-dose options could command premium pricing.
Risks and Barriers
- Intense generic competition lowers margins.
- Potential safety concerns or adverse events could limit growth.
- Hospital budget constraints delay procurement or-reduction in use.
Key Takeaways
- The U.S. market for dexmedetomidine (NDC 45802-0066) is projected to decline in price owing to generic entry but grow in volume.
- Prices of generics are expected to stabilize around $42-$44 per vial by 2026.
- Market expansion in non-hospital settings and emerging economies offers long-term growth.
- Patent expiry in 2021 has accelerated price erosion; no new patents or exclusivity expected.
- Value-based reimbursement strategies and safety profile improvements could influence future market dynamics.
FAQs
1. What is the primary therapeutic use of dexmedetomidine?
Dexmedetomidine is used for sedation in intensive care units and procedural anesthesia due to its sedative, anxiolytic, and analgesic properties without significant respiratory depression.
2. How have patent expirations affected the pricing landscape?
Patent expirations in 2021 introduced generics, reducing prices for dexmedetomidine products by approximately 25-30%. This price competition is expected to continue, putting downward pressure on branded product pricing.
3. What is the growth outlook for this drug in emerging markets?
Emerging markets are experiencing increased hospital infrastructure development and procedural volume, offering potential growth despite price sensitivity. Local generic manufacturing further enhances competitive pricing.
4. Are there anticipated regulatory changes that could impact this market?
No immediate regulatory changes are forecasted. However, expanded indications and additional formulations could influence future market size and pricing.
5. What are key considerations for investors in this drug's market?
Investors should monitor patent status, generic market entry, hospital adoption rates, reimbursement trends, and emerging competition from alternative sedatives or formulations.
References
[1] FDA. (2022). Dexmedetomidine drug approval information. U.S. Food and Drug Administration.
[2] IQVIA. (2022). Hospital and outpatient drug market analysis.
[3] ReportLinker. (2023). Global dexmedetomidine market forecast.
[4] Medtech and Pharma Market Reports. (2023). Price trends for sedatives.
